British Smaller Companies VCT PLC
23 July 2004
BRITISH SMALLER COMPANIES VCT PLC ('the Company')
ANNUAL GENERAL MEETING
The Company announces that the Annual General Meeting was held on 22 July 2004
and all the resolutions proposed were passed.
Commenting on progress in the first quarter of the new financial year, the
Chairman, Sir Andrew Hugh Smith, said, 'The directors are satisfied with the
progress of a number of our investee companies. In continuance of our policy to
report net asset values on a quarterly basis, the latest net asset value per
share, as at 30 June 2004, is 72.2p, broadly similar to the year end figure. We
anticipate an increase in net asset value during the remainder of the year.'
One of the investee companies, Cozart plc, has successfully completed an IPO.
Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse. It is a major supplier of these tests to the Home Office. First dealings
in Cozart shares will commence on Monday 26 July.
ENDS
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.